26 May 2023 - If granted by the European Commission, Veklury will become the first and only authorised anti-viral treatment ...
26 May 2023 - Regulatory processes are continuing in other countries including the US. ...
26 May 2023 - Novo Nordisk today announced that the EMA's CHMP has adopted a positive opinion, recommending once weekly Sogroya ...
26 May 2023 - The EMA’s CHMP has recommended revoking the marketing authorisation for Adakveo (crizanlizumab), a medicine for preventing ...
26 May 2023 - The European Commission decision is expected within 67 days of the CHMP opinion. ...
26 May 2023 - Recommendation based on results from the Phase 3 CheckMate-816 trial, in which Opdivo with chemotherapy demonstrated improved ...
26 May 2023 - The EMA’s CHMP recommended two medicines for approval at its May 2023 meeting. ...
10 May 2023 - Ultomiris transforms the treatment landscape for anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients, with potential to eliminate ...
5 May 2023 - PEGylated enzyme replacement therapy designed to provide a long half-life. ...
4 May 2023 - If granted by the European Commission, Hepcludex will become the only approved treatment for HDV in the ...
3 May 2023 - Approval of Breyanzi based on the pivotal Phase 3 TRANSFORM trial, in which Breyanzi significantly improved ...
27 April 2023 - Taiho Pharmaceutical announced today that the EMA's CHMP has issued a positive opinion recommending the conditional ...
27 April 2023 - Positive CHMP opinions are supported by data from four Phase 3 studies that evaluated bimekizumab in active ...
26 April 2023 - Positive opinion paves way for first new treatment option in hidradenitis suppurativa in nearly a decade. ...
26 April 2023 - The recommendation is based on results from the Phase I/II NP30179 study, where Columvi given as a ...